Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics is a clinical-stage company specializing in developing treatments for genetically driven neuromuscular diseases using its proprietary FORCE platform. Despite the potential risks associated with its platform and regulatory pathway, Dyne's lead programs have shown promising biomarker and functional improvements, with a potential launch timeline of 1H28 for its lead program, Z-basivarsen. Additionally, Dyne has a diverse pipeline of candidates targeting various indications, with potential market opportunities in FSHD and Pompe disease. Overall, these factors suggest a positive outlook for Dyne Therapeutics with potential for long-term growth and success.

Bears say

Dyne Therapeutics is a clinical-stage neuromuscular disease company with a focused mission. However, the company is currently facing intense competition in the gene therapies and oligonucleotide medicines space, and its pipeline of therapies is still in the early stages of development. There is also a risk of future dilution for investors if the company needs to raise capital to support its research and development efforts. The company's current valuation is supported by the potential of their lead candidate Z-rostudirsen for Duchenne muscular dystrophy, but this success may not be replicated by other pipeline assets.

Dyne Therapeutics (DYN) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 9 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.